Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibodies Evolve

This article was originally published in Start Up

Executive Summary

Methods for discovering and developing therapeutic antibodies are evolving along with clinical and commercial expectations and practices; at the cutting edge of a mature field, new players strive to improve upon existing therapeutic antibodies. Profiles of GamaMabs, Numab, and Zebra Biologics.

You may also be interested in...

Zebra Biologics Inc.

Zebra Biologics Inc. has a new way of creating antibodies that allows huge numbers of candidates to be quickly identified through a functional assay, using lentivirus to transfect an autocrine human cell line specially engineered to change color if anything (presumably the encoded fragment) activates a given receptor. 

Numab AG

Swiss start-up Numab AG’s discovery platform includes a method of generating diverse antibodies by immunizing rabbits. Antibodies produced in this species are widely used for diagnostic purposes, and appreciated for their “high affinity,” but few companies have ever pursued rabbits as a source of therapeutic antibodies, largely because they have been difficult to isolate; Numab appears to have figured out an elegant way to do so.

GamaMabs Pharma SA

GamaMabs Pharma SA is one of the latest contenders aiming to boost the biological activity of antibodies by altering their attached sugar groups. The company, located in Toulouse, France, was founded in June 2013 to develop therapeutic antibody treatments for gynecologic cancers, using core technologies licensed from the French Laboratories for Biotechnologies.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts